Recommendations for treating children with drug-resistant tuberculosis

Luisa Galli, Laura Lancella, Silvia Garazzino, Marina Tadolini, Alberto Matteelli, Giovanni Battista Migliori, Nicola Principi, Alberto Villani, Susanna Esposito, Italian Pediatric TB Study Group, Giuseppe Losurdo

Research output: Contribution to journalArticle

Abstract

Tuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious disease throughout the world. The number of cases of multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), which are characterised by high mortality rates, is increasing. The therapeutic management of children with MDR- and XDR-TB is complicated by a lack of knowledge, and the fact that many potentially useful drugs are not registered for pediatric use and there are no formulations suitable for children in the first years of life. Furthermore, most of the available drugs are burdened by major adverse events that need to be taken into account, particularly in the case of prolonged therapy. This document describes the recommendations of a group of scientific societies on the therapeutic approach to pediatric MDR- and XDR-TB. On the basis of a systematic literature review and their personal clinical experience, the experts recommend that children with active TB caused by a drug-resistant strain of Mycobacterium tuberculosis should always be referred to a specialised centre because of the complexity of patient management, the paucity of pediatric data, and the high incidence of adverse events due to second-line anti-TB treatment.

Original languageEnglish
Pages (from-to)176-82
Number of pages7
JournalPharmacological Research
Volume105
DOIs
Publication statusPublished - Mar 2016

Fingerprint

Multidrug-Resistant Tuberculosis
Tuberculosis
Pediatrics
Communicable Diseases
Extensively Drug-Resistant Tuberculosis
Pharmaceutical Preparations
Therapeutics
Mycobacterium tuberculosis
Cause of Death
Mortality
Incidence

Keywords

  • Antitubercular Agents
  • Child
  • Extensively Drug-Resistant Tuberculosis
  • Humans
  • Mycobacterium tuberculosis
  • Practice Guidelines as Topic
  • Tuberculosis, Multidrug-Resistant
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Cite this

Galli, L., Lancella, L., Garazzino, S., Tadolini, M., Matteelli, A., Migliori, G. B., ... Losurdo, G. (2016). Recommendations for treating children with drug-resistant tuberculosis. Pharmacological Research, 105, 176-82. https://doi.org/10.1016/j.phrs.2016.01.020

Recommendations for treating children with drug-resistant tuberculosis. / Galli, Luisa; Lancella, Laura; Garazzino, Silvia; Tadolini, Marina; Matteelli, Alberto; Migliori, Giovanni Battista; Principi, Nicola; Villani, Alberto; Esposito, Susanna; Italian Pediatric TB Study Group ; Losurdo, Giuseppe.

In: Pharmacological Research, Vol. 105, 03.2016, p. 176-82.

Research output: Contribution to journalArticle

Galli, L, Lancella, L, Garazzino, S, Tadolini, M, Matteelli, A, Migliori, GB, Principi, N, Villani, A, Esposito, S, Italian Pediatric TB Study Group & Losurdo, G 2016, 'Recommendations for treating children with drug-resistant tuberculosis', Pharmacological Research, vol. 105, pp. 176-82. https://doi.org/10.1016/j.phrs.2016.01.020
Galli L, Lancella L, Garazzino S, Tadolini M, Matteelli A, Migliori GB et al. Recommendations for treating children with drug-resistant tuberculosis. Pharmacological Research. 2016 Mar;105:176-82. https://doi.org/10.1016/j.phrs.2016.01.020
Galli, Luisa ; Lancella, Laura ; Garazzino, Silvia ; Tadolini, Marina ; Matteelli, Alberto ; Migliori, Giovanni Battista ; Principi, Nicola ; Villani, Alberto ; Esposito, Susanna ; Italian Pediatric TB Study Group ; Losurdo, Giuseppe. / Recommendations for treating children with drug-resistant tuberculosis. In: Pharmacological Research. 2016 ; Vol. 105. pp. 176-82.
@article{f5397de8e8334ec99823691ea7e6b807,
title = "Recommendations for treating children with drug-resistant tuberculosis",
abstract = "Tuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious disease throughout the world. The number of cases of multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), which are characterised by high mortality rates, is increasing. The therapeutic management of children with MDR- and XDR-TB is complicated by a lack of knowledge, and the fact that many potentially useful drugs are not registered for pediatric use and there are no formulations suitable for children in the first years of life. Furthermore, most of the available drugs are burdened by major adverse events that need to be taken into account, particularly in the case of prolonged therapy. This document describes the recommendations of a group of scientific societies on the therapeutic approach to pediatric MDR- and XDR-TB. On the basis of a systematic literature review and their personal clinical experience, the experts recommend that children with active TB caused by a drug-resistant strain of Mycobacterium tuberculosis should always be referred to a specialised centre because of the complexity of patient management, the paucity of pediatric data, and the high incidence of adverse events due to second-line anti-TB treatment.",
keywords = "Antitubercular Agents, Child, Extensively Drug-Resistant Tuberculosis, Humans, Mycobacterium tuberculosis, Practice Guidelines as Topic, Tuberculosis, Multidrug-Resistant, Journal Article, Research Support, Non-U.S. Gov't, Review",
author = "Luisa Galli and Laura Lancella and Silvia Garazzino and Marina Tadolini and Alberto Matteelli and Migliori, {Giovanni Battista} and Nicola Principi and Alberto Villani and Susanna Esposito and {Italian Pediatric TB Study Group} and Giuseppe Losurdo",
note = "Copyright {\circledC} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = "3",
doi = "10.1016/j.phrs.2016.01.020",
language = "English",
volume = "105",
pages = "176--82",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Recommendations for treating children with drug-resistant tuberculosis

AU - Galli, Luisa

AU - Lancella, Laura

AU - Garazzino, Silvia

AU - Tadolini, Marina

AU - Matteelli, Alberto

AU - Migliori, Giovanni Battista

AU - Principi, Nicola

AU - Villani, Alberto

AU - Esposito, Susanna

AU - Italian Pediatric TB Study Group

AU - Losurdo, Giuseppe

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/3

Y1 - 2016/3

N2 - Tuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious disease throughout the world. The number of cases of multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), which are characterised by high mortality rates, is increasing. The therapeutic management of children with MDR- and XDR-TB is complicated by a lack of knowledge, and the fact that many potentially useful drugs are not registered for pediatric use and there are no formulations suitable for children in the first years of life. Furthermore, most of the available drugs are burdened by major adverse events that need to be taken into account, particularly in the case of prolonged therapy. This document describes the recommendations of a group of scientific societies on the therapeutic approach to pediatric MDR- and XDR-TB. On the basis of a systematic literature review and their personal clinical experience, the experts recommend that children with active TB caused by a drug-resistant strain of Mycobacterium tuberculosis should always be referred to a specialised centre because of the complexity of patient management, the paucity of pediatric data, and the high incidence of adverse events due to second-line anti-TB treatment.

AB - Tuberculosis (TB) is still one of the most difficult infectious diseases to treat, and the second most frequent cause of death due to infectious disease throughout the world. The number of cases of multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB), which are characterised by high mortality rates, is increasing. The therapeutic management of children with MDR- and XDR-TB is complicated by a lack of knowledge, and the fact that many potentially useful drugs are not registered for pediatric use and there are no formulations suitable for children in the first years of life. Furthermore, most of the available drugs are burdened by major adverse events that need to be taken into account, particularly in the case of prolonged therapy. This document describes the recommendations of a group of scientific societies on the therapeutic approach to pediatric MDR- and XDR-TB. On the basis of a systematic literature review and their personal clinical experience, the experts recommend that children with active TB caused by a drug-resistant strain of Mycobacterium tuberculosis should always be referred to a specialised centre because of the complexity of patient management, the paucity of pediatric data, and the high incidence of adverse events due to second-line anti-TB treatment.

KW - Antitubercular Agents

KW - Child

KW - Extensively Drug-Resistant Tuberculosis

KW - Humans

KW - Mycobacterium tuberculosis

KW - Practice Guidelines as Topic

KW - Tuberculosis, Multidrug-Resistant

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1016/j.phrs.2016.01.020

DO - 10.1016/j.phrs.2016.01.020

M3 - Article

C2 - 26821118

VL - 105

SP - 176

EP - 182

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -